Updated:
GeoVax Labs, Inc.
GeoVax Labs, Inc. (GOVX) is a publicly traded biotech developing vaccines for infectious diseases and cancers, with no disclosed investment portfolio.
Overview
GeoVax Inc maintains a profile on LinkedIn. The account lists 18 followers.
General information
Frequently asked questions
What is GeoVax Labs' primary business?
It is a clinical-stage biotech using its MVA viral vector platform to create vaccines for COVID-19, HIV, and cancers. Its revenue comes from grants, partnerships, and equity raises, not investment returns.
Does GeoVax Labs make direct investments or back external funds?
No. GeoVax is not an investment firm. It focuses on research and development of vaccine candidates, with no publicly disclosed investment portfolio or fund commitments.
What is the source of GeoVax Labs' funding?
GeoVax raises capital through public equity offerings, government grants (e.g., from the U.S. National Institutes of Health), and collaborative agreements. It does not manage an externally invested fund.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: